Acronyms and abbreviations -April 2024

AAHI Access to Advanced Health Institute

Ab antibody

ACT-UP AIDS Coalition to Unleash Power

ACTG formerly AIDS Clinical Trials Group, now Advancing Clinical Therapeutics

Globally

Ad adenovirus (followed by a number indicating the strain/type)

ADA anti-drug antibody

ADCC antibody-dependent cellular cytotoxicity
ADCP antibody-dependent cellular phagocytosis

AE adverse event

AEC absolute eosinophil count
AESI adverse event of special interest

AF aqueous formulation

AFAB assigned female sex at birth

Ag antigen

AHRI Africa Health Research Institute
AIDS acquired immunodeficiency syndrome

AIDSInfo US Federal website for AIDS information (http://www.aidsinfo.nih.gov)

AIM assay activation induced marker assay
ALT alanine aminotransferase

Alum aluminum hydroxide suspension AMAB assigned male sex at birth

AmFAR American Foundation for AIDS Research

AMP antibody mediated prevention

ANOVA analysis of variance

AoU assessment of understanding
ART or ARV antiretroviral therapy
ASO AIDS service organization
AST aspartate aminotransferase
AUC or AUTC area under the curve

AUCMB area under the magnitude breadth curve AVAC AIDS Vaccine Advocacy Coalition

AVEG AIDS Vaccine Evaluation Group (predecessor network to HVTN)

AVRS AIDS Vaccine Research Subcommittee (NIAID)

β-HCG beta human chorionic gonadotropin

B cell seq B cell mRNA sequencing

BAMA binding antibody multiplex assay

BCG bacille Calmette-Guérin (preventive TB vaccine)

BCP B-cell phenotyping BCR B-cell receptor

BIP Baseline Immunogenicity Predictors

BLI BioLayer Interferometry

BMGF Bill and Melinda Gates Foundation

BMI body mass index

bnAb broadly neutralizing antibody (capitalization may vary)

BP blood pressure

BRR Bill of Rights and Responsibilities, for HIV or TB vaccine trials

BSL biosafety level

CAB/CAG community advisory board/group

CAPRISA Centre for the AIDS Programme of Research in South Africa

CBC complete blood count

CBO community-based organization

CBPR community based participatory research

CD4bs CD4 binding site

CDC Centers for Disease Control and Prevention (US)

CDM Clinical Data Manager
CE community engagement
CER Community Educator/Recruiter
CFAR Center for AIDS Research

CFAR-GAP Center for AIDS Research – GCLP Compliant AIDS Program

CFR Code of Federal Regulations (US)

CFU colony forming units

CGG chronic granulomatous disease

CHAVD Consortium for HIV/AIDS Vaccine Development (Scripps)

CHAVI-ID Center for HIV/AIDS Vaccine Immunology – Immunogen Discovery (NIAID)

CHIL Cape Town HVTN Immunology Lab

CHO Chinese hamster ovary
CI confidence interval

CIOMS Council for International Organizations of Medical Sciences

CMIA chemiluminescent microparticle immunoassay

CMV cytomegalovirus

COMPASS combinatorial polyfunctionality analysis of antigen-specific T-cell subsets

CoP correlate of protection CoR correlate of risk

CoVPN COVID-19 Prevention Network

CP Community Partners (a cross-network CAB convened by HANC)

CRAN Comprehensive R Archive Network

CRF case report form

CRMS Clinical Research Management System (NIAID)

CRS clinical research site

CRPMC Clinical Research Products Management Center (NIAID)

Cryo-EM cryogenic electron microscopy

CSF cerebrospinal fluid
CSS Clinical Safety Specialist
CSW commercial sex worker
CTA clinical trials agreement
CTL cytotoxic T-lymphocyte
CTM Clinical Trials Manager
CTU clinical trials unit

DAERS DAIDS Adverse Experience Reporting System

DAIDS Division of AIDS (at NIAID)

DHHS Department of Health and Human Services (US)

DHVI Duke Human Vaccine Institute
DTH delayed-type hypersensitivity

DM diabetes mellitus

DOV discontinuation of vaccination

DS disulfide

EAE expedited adverse event EC ethics committee

EC50 half-maximal effective concentration eGFR estimated glomerular filtration rate

EIA enzyme immunoassay

ELISA enzyme-linked immunosorbent assay ELISpot enzyme-linked immunosorbent spot

EM electron microscopy

EMPEM electron microscopy—based polyclonal epitome mapping

EMT Executive Management Team (HVTN)

Env envelope protein of HIV EQA external quality assurance

EQAPOL external quality assurance program oversight laboratory

ETWG Efficacy Trials Working Group (HVTN)

EUA Emergency Use Authorization

EUL emergency use listing

EUROVACC European Vaccine Effort Against HIV/AIDS

FBO faith-based organization

FcR Fc- receptors

FDA Food and Drug Administration (US)

FHCC Fred Hutchinson Cancer Center, or Fred Hutch

FIH first-in-human
FP fusion peptide
FPR false positive rate
FS functionality score

GC germinal center GCP Good Clinical Practice

GCLP Good Clinical Laboratory Practice
GEE generalized estimating equation

GINA Genetic Information Nondiscrimination Act

GMP Good Manufacturing Practice
GPP Good Participatory Practice

HANC Office of HIV/AIDS Network Coordination (NIAID, located at Fred Hutch)

HBsAg hepatitis B surface antigen

HCRISA Hutchinson Centre Research Institute of South Africa

HCV hepatitis C virus Hgb hemoglobin

HHS Department of Health and Human Services (US)

HIPAA Health Insurance Portability and Accountability Act (US)

HIVNET HIV Network for Prevention Trials (NIAID, closed October 1999)

HIT heparin-induced thrombocytopenia
HIV human immunodeficiency virus
HLA human leukocyte antigen
HPTN HIV Prevention Trials Network
HSV2 herpes simplex virus type 2
HVTN HIV Vaccine Trials Network

IAS-USA International Antiviral Society – USA IAVI International AIDS Vaccine Initiative

IB Investigator's Brochure

IBC Institutional Biosafety Committee

IC50 inhibitory concentration of 50% (median)

IC80 inhibitory concentration of 80% ICABA infected cells antibody binding assay

ICH International Council for Harmonisation of Technical Requirements for

Pharmaceuticals for Human Use

ICS intracellular cytokine staining assay

ID intradermal

ID50 50% inhibitory dose (median)

ID80 80% inhibitory dose IFN-γ interferon-gamma Ig immunoglobulin IgA immunoglobulin A IgG immunoglobulin G IgM immunoglobulin M

IGRA interferon-gamma release assay

IL interleukin IM intramuscular

IMPAACT International Maternal Pediatric Adolescent AIDS Clinical Trials

IN intranasal

IND Investigational New Drug (application to FDA)

INH isoniazid

INR international normalized ratio IoR Investigator of Record

IRAMP International Research and Mentorship Program (HVTN)

IRB Institutional Review Board IRM immune response modifier

ITT intent-to-treat
IUD intrauterine device
IV intravenous

KI knock-in KO knock-out

KZN KwaZulu Natal (South Africa)

LABA long-acting beta agonist LAM lipoarabinomannan

LC Laboratory Center (of the HVTN)

LOC Leadership and Operations Center (of the HVTN)

LS an antibody half-life extension mutation on the Fc region of an antibody

LTFU lost to follow-up OR long term follow-up

MAAE medically attended adverse event

mAb monoclonal antibody MAR missing at random

MCAR missing completely at random

MCC Medicines Control Council (South Africa)

Mcg microgram

MedDRA Medical Dictionary for Regulatory Activities

MFI mean fluorescence intensity
MHC major histocompatibility complex
MIF macrophage migration inhibitory factor
MIMOSA mixture models for single-cell assays

MLV murine leukemia virus

MMR measles, mumps, and rubella vaccine

MO Medical Officer (DAIDS)

MOP Manual of Operations Procedures
MPER membrane proximal external region
MRC Medical Research Council (South Africa)

MSD Meso Scale Discovery assay
MSM men who have sex with men
M.tb Mycobacterium tuberculosis
MTBC M. tuberculosis complex
MVA modified Ankara virus

nAb neutralizing antibody nnAb non-neutralizing antibody

NAT nucleic acid test

NB non-binary

NEC Network Evaluation Committee (HVTN)

NFL native flexibly linked

NGO non-governmental organization

NHP nonhuman primate NK natural killer cells

NIAID National Institute of Allergy and Infectious Diseases (of the US NIH)

NICD National Institute for Communicable Diseases (South Africa)

NIH National Institutes of Health NLT native-like HIV Env trimer

NSAID nonsteroidal anti-inflammatory drug

OAR Office of AIDS Research (NIH)

OARAC Office of AIDS Research Advisory Committee (NIH)

OBA Office of Biotechnology Activities (NIH)

OCGR Office of Communications and Government Relations (NIAID)

OHRP Office for Human Research Protections (at the NIH)
OPCRO Office for Policy in Clinical Research Operations (NIAID)

OPV oral polio vaccine

PAB Pharmaceutical Affairs Branch (NIAID)
PBMC peripheral blood mononuclear cell
PBS phosphate-buffered saline

PBS phosphate-buffered saline
PCA principal component analysis
PCR polymerase chain reaction
PD pharmacodynamics
PDB protocol database

PDIM phthiocerol dimycocerosate PDM Protocol Development Manager

PK pharmacokinetics
PM Project Manager
PE prevention efficacy
PEF peak expiratory flow
PEP post-exposure prophylaxis
PFS polyfunctionality score

PHRU Perinatal HIV Research Unit (site in Soweto)

PI Principal Investigator
PID pelvic inflammatory disease

PIMMC potential immune-mediated medical condition

Pol polymerase (generally of HIV)
PrEP pre-exposure prophylaxis
PSRT Protocol Safety Review Team
PT preferred term OR protocol team

PT50 predicted serum neutralization 50% inhibitory dilution titer biomarker (ID50) PT80 predicted serum neutralization 80% inhibitory dilution titer biomarker (ID80)

PTL Protocol Team Leader
PWH people with HIV
PLWH people living with HIV
POD prevention of disease

POPIA Protection of Personal Information Act (South Africa)

PPD purified protein derivative; also the name of DAIDS' contracted study

monitoring agency

PSRC Prevention Science Review Committee (DAIDS)

PSRT Protocol Safety Review Team
PTE potential T-cell epitope

QADVIP Quality Assurance for Duke Vaccine Immunogenicity Programs

QAU Quality Assurance Unit QFT Quantiferon tuberculosis

qPCR quantitative polymerase chain reaction

RA regulatory authority

RAB Regulatory Affairs Branch (NIAID)

RAMP Research and Mentorship Program (HVTN)

RBD receptor binding domain RCT randomized controlled trial

RE regulatory entity

REDCap Research Electronic Data Capture

RhCMV rhesus cytomegalovirus RML Regional Medical Liaison

RNA-Seq RNA sequencing

RSC Regulatory Support Center at DAIDS

SA specific activity

SAAVI South African AIDS Vaccine Initiative

SAE serious adverse event

SAHPRA South African Health Products Regulatory Authority

SAP statistical analysis plan SAS statistical analysis system

SATVI South African TB Vaccine Initiative
SBS social and behavioral sciences

SBS-CEU Social & Behavioral Sciences and Community Engagement Unit (HVTN)

SBWG Social and Behavioral Sciences Working Group (HVTN)

SC subcutaneous

SCHARP Statistical Center for HIV/AIDS Research and Prevention (serves as HVTN's

SDMC)

SCID severe combined immunodeficient

SCORE Site Clinical Operations and Research Essentials (manual)

SD standard deviation

SDMC Statistics and Data Management Center SEG Special Emphasis Group (Laboratory)

SFC spot-forming cell SFU spot-forming unit

SGC Scientific Governance Committee (HVTN)

SHD standard human dose

SHIV simian-human immunodeficiency virus

SICF sample informed consent form

sIgA secretory IgA

SIV simian immunodeficiency virus

SLD Scientific Leadership Development program (HVTN)

SMB Safety Monitoring Board
SMQ Standard MedDRA Query
SOP standard operating procedures

SPT Safety and Pharmacovigilance Team (DAIDS)
SRC Scientific Review Committee (HVTN)

SSP study-specific procedures

STI /D sexually transmitted infection/disease

SUDL Specimen Use Decision Log

SUSAR suspected unexpected serious adverse reaction

TAG Treatment Action Group

TB tuberculosis

TBVI Tuberculosis Vaccine Initiative
TCID50 median tissue culture infectious dose
TEAE treatment emergent adverse event

TG transgender, also "trans"
TGNB transgender and non-binary

TLR toll-like receptor

TMLE targeted minimum loss-based estimation TPT tuberculosis preventive treatment

TST tuberculin skin test
TT tetanus toxoid

TTS thrombosis with thrombocytopenia syndrome

μ micro μg microgram

ULN/ULQ upper limit of normal/upper limit of quantitation
UNAIDS Joint United Nations Programme on HIV/AIDS
USAID United States Agency for International Development

USMHRP US Military HIV Research Program

USP United States Pharmacopeia

UW-VSL University of Washington Virology Specialty Laboratory

VAERS Vaccine Adverse Event Reporting System (through CDC)

VAX300 VaxINator Intranasal Atomization Device
VISC Vaccine Immunology Statistical Center
VISP/r vaccine-induced seropositivity/seroreactivity

VL viral load VP viral particle

VRC Dale and Betty Bumpers Vaccine Research Center (at NIAID)

WBC white blood cell

WCL whole cell lysate (of TB)

WG working group

WHO World Health Organization

WRAIR Walter Reed Army Institute of Research

WT wild-type